Anti-Ro52 antibodies in idiopathic inflammatory myopathies: clinical significance across myositis-specific antibody–defined subgroups
Authors' conclusion
Anti-Ro52 antibodies are highly prevalent in patients with IIMs, especially those with anti-MDA5 + DM and ASyS.
Study context
- Population
- Patients with IIM treated at the China-Japan Friendship Hospital, April 2002–April 2023
- Participants
- 2,126 patients
- Exposure
- Anti-Ro52 positive vs anti-Ro52 negative IIM patients, within MSA-defined subgroups
- Anti-Ro52+n = 978
- Outcome
- Frequency, clinical characteristics and prognostic value of anti-Ro52 antibodies, especially in MSA-defined IIM subgroups
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
Anti-Ro52 positivity (frequency)
Anti-Ro52+
46.0%
978
Observational data: associations, not effects.
Original publication
Anti-Ro52 antibodies in idiopathic inflammatory myopathies: clinical significance across myositis-specific antibody–defined subgroups. Rheumatology (Oxford). Published 26 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →